New FDA Reporting Requirement For Oxygen Transfillers

Published in Government Relations on January 07, 2022

DME providers who transfill oxygen appear to now be required to submit reports to the FDA to show how many units of certain drugs, including medical gases (oxygen) they dispensed. Until now, providers who transfilled oxygen were required to simply register with the FDA, but there was no reporting requirement. The new reporting requirement stems from the CARES Act, which modified the Food, Drug, and Cosmetics (FD&C) Act.

In 2022, the first year of the reporting requirements, there will be two reports due, one for 2020 and one for 2021. Reports for calendar year 2020 should be submitted no later than February 15, 2022, and reports for calendar year 2021 should be submitted no later than May 16, 2022. Reports for subsequent calendar years should be submitted no later than February 15 of the following year. Each report submitted must include the listed drug, identified by its National Drug Code (NDC), and be organized by the amount of drug released each month. DME providers reporting on the amount of oxygen they dispensed will need to report quantities for each size of gaseous cylinder or liquid reservoir that was transfilled.

Based on our interpretation of the guidance, the term “transfiller” would include companies that fill liquid and/or gaseous oxygen reservoirs/cylinders/containers, etc.

The full draft guidance from the FDA can be found here: https://www.federalregister.gov/documents/2021/11/01/2021-23722/reporting-amount-of-listed-drugs-and-biological-products-under-section-510j3-of-the-federal-food. An excerpt from that guidance reads: The “FDA is announcing the availability of a draft guidance for industry entitled “Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act.” On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted to aid response efforts and ease the economic impact of the Coronavirus Disease 2019 (COVID-19). In addition, the CARES Act included authorities to enhance FDA's ability to identify, prevent, and mitigate possible drug shortages by, among other things, improving FDA's visibility into drug supply chains. Section 3112(e) of the CARES Act (Pub. L. 116-136) added section 510(j)(3) of the FD&C Act (21 U.S.C. 360(j)(3)) to require that each person (including repackers and relabelers) who registers with FDA under section 510 of the FD&C Act with regard to a drug must report annually to FDA the amount of each listed drug that was manufactured, prepared, propagated, compounded, or processed by such person for commercial distribution.

This draft guidance is intended to assist registrants of drug establishments in submitting to FDA reports on the amount of each listed drug manufactured, prepared, propagated, compounded, or processed for commercial distribution, as required by section 510(j)(3) of the FD&C Act. The draft guidance addresses the content of reports, the timing of reports, and the process for report submission.

This draft guidance describes the process that should be used for reporting by each person who registers with FDA under section 510 of the FD&C Act with regard to a listed drug (including a finished dosage form product, an active pharmaceutical ingredient, and other listed drugs), except for biological products or categories thereof exempted by an order under section 510(j)(3)(B)). The process described in this guidance applies to such reporting with respect to listed drugs, including medical gases…”

The definition of “medical gas” in Section 575 of the FD&C Act includes oxygen, nitrogen, nitrous oxide, carbon dioxide, helium, carbon monoxide, and medical air.

Some helpful links that provide additional information related to this topic are listed below:

Portal that providers will initially register and ultimately submit their reports to the FDA: https://edm.fda.gov/EDMIDPLogin/welcome?response_type=code&client_id=0oa1as7rb2poiYTch297&scope=openid%20profile&state=1097800867_1640719521396&redirect_uri=https%3A%2F%2Fedm.fda.gov%2Foidcclient%2Fedmrp

Draft guidance issued by the FDA: https://www.fda.gov/media/153665/download

CARES Act: https://www.congress.gov/116/bills/hr748/BILLS-116hr748enr.pdf

FD&C Act: https://www.govinfo.gov/content/pkg/COMPS-973/pdf/COMPS-973.pdf


TAGS

  1. general
  2. regulatory

From Our Experts

H.R. 5555 Gets Approved By Health Subcommittee thumbnail H.R. 5555 Gets Approved By Health Subcommittee On Wednesday, Nov. 15, the Health Subcommittee convened the health markup. The DMEPOS Relief Act of 2023 (H.R. 5555) was included in the discussion and approved. H.R. 5555 will now move on to the Energy and Commerce committee for consideration in the next few weeks. Important HME Legislation Being Discussed By Health Subcommittee on Wednesday thumbnail Important HME Legislation Being Discussed By Health Subcommittee on Wednesday On Wednesday, Nov. 15, the Health Subcommittee of the House Energy and Commerce Committee is set to meet and discuss important legislation. Included in this session will be H.R. 5555, DMEPOS Relief Act of 2023. This bill, led by Rep. Miller-Meeks (IA) and Rep. Tonko (NY) provides much-needed reimbursement relief. Read the full public memo here. Ronda Vlog: CGM News - Update On the 90 Days Billable on January 1, 2024 thumbnail Ronda Vlog: CGM News - Update On the 90 Days Billable on January 1, 2024 Be sure to listen to this important video update from Ronda Buhrmester on the upcoming change on how to bill a 90-day supply for CGMs. VGM's Ike Isaacson Gets 'Revved Up' thumbnail VGM's Ike Isaacson Gets 'Revved Up' WATERLOO, Iowa – A singular focus and a singular voice: That's what it takes to get the HME industry's message across to both lawmakers and regulators, says Mike “Ike” Isaacson, who was recently named senior vice president of government relations at VGM & Associates. A Summary of the Final Rule on the Lymphedema Treatment Act Recently Released by CMS thumbnail A Summary of the Final Rule on the Lymphedema Treatment Act Recently Released by CMS Craig Douglas, VP of Payer Relations, VGM and Associates, has reviewed the document and summarized the important information. Champions of Change Pushing for 55 in 55 Make Moves in Illinois thumbnail Champions of Change Pushing for 55 in 55 Make Moves in Illinois Champions of Change are making a strong start in the push for 55 in 55 (The goal of 55 in 55 is to schedule 55 visits with legislators and/or their staff in 55 days). Yesterday, a room of nearly 20 people gathered at VGM member, Prism Health Care Services in Schaumburg, IL to discuss S. 1294, current DME rates impacted by supply chain, delivery costs, employee costs, inflation, and so much more. Ronda Vlog: CGM News -90 Days Billable on January 1, 2024 thumbnail Ronda Vlog: CGM News -90 Days Billable on January 1, 2024 Listen as Ronda Buhrmester, Sr. Director of Payer Relations and Reimbursement, provides an important CGM update. S. 3069 Introduced Into Senate thumbnail S. 3069 Introduced Into Senate On Oct. 18, U.S. Senators Tammy Duckworth (D-IL) and Lisa Murkowski (R-AK) re-introduced legislation to ensure breast cancer patients and survivors who have experienced a mastectomy are able to access custom breast prosthetics under Medicare.